Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain
Crossref DOI link: https://doi.org/10.1186/s12962-015-0037-9
Published Online: 2015-06-09
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hidalgo-Vega, Álvaro
Villoro, Renata
Blasco, Juan Antonio
Talavera, Pablo
Ferro, Belén
Purcaru, Oana
License valid from 2015-06-09